Lumida
/CAH
⌘K
Cardinal Health Inc

Cardinal Health Inc

CAH
$228.52USD↓-0.09%-0.20 today

MARKET CAP

53.5B

P/E (TTM)

21.9x

FWD P/E

19.2x

DAY RANGE

$228 – $233

52W RANGE

$138
$243

AI Summary

Stalk
TrimMedium

CAH remains in Stage 3 distribution despite its long-term uptrend. Medium-term structure is bearish, reinforced by the Double Top and repeated failures at the 9/21 EMAs. An active Lockout Rally triggers a short-term bullish timing override but conflicts with the bearish medium-term bias. Execution should be deferred: trim into the 9/21 EMA resistance zone on rejection.

  • ↑Q3 revenue $61B (+11% YoY), driven by pharmaceutical and specialty demand.
  • ↑Raised full-year EPS target to $10.70–$10.80, signaling ~30% growth.
  • ↓Valuation stretched vs. peers on P/E multiple, risking correction.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Cardinal Health, Inc. (NYSE: CAH) operates as a leading provider of healthcare services and products, specializing in the distribution of pharmaceuticals and medical products. The company maintains a significant presence in the healthcare market, bridging clinical and operational solutions while focusing on high-growth areas like specialty care. Cardinal Health is well-positioned amid evolving healthcare dynamics, particularly benefiting from growing demand for specialty pharmaceuticals and integrated services that enhance patient care.

Bull says

  • ↑Q3 revenue $61B (+11% YoY), driven by pharmaceutical and specialty demand.
  • ↑Raised full-year EPS target to $10.70–$10.80, signaling ~30% growth.
  • ↑Acquisition of Solaris Health boosts specialty solutions platform synergies.
  • ↑Deploying $1B in FY26 buybacks reflects strong cash flow discipline.
  • ↑Specialty pharma revenue expected >$50B in FY26 on GLP-1 demand.
  • ↑High profitability and momentum factors; efficient leverage and low volatility.

Bear says

  • ↓Valuation stretched vs. peers on P/E multiple, risking correction.
  • ↓Negative earnings yield and weak book-to-price factors highlight overvaluation.
  • ↓Low analyst revisions score suggests downside earnings pressure ahead.
  • ↓IRA-driven pricing cuts cut Q3 revenue by six percentage points.
  • ↓Solaris Health integration may face synergy delays and execution risks.
  • ↓Distribution volumes remain vulnerable to competition and economic pressures.

Investment themes with CAH

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q3 2026 · Mgmt. Guidance

Updated 04-30-2026bullish

Transcript signals

Bull points

  • Our team delivered strong financial results in the third quarter, reflecting positive and broad-based demand, operational execution, and loyalty to our disciplined capital allocation framework.
  • Given our confidence in the remainder of the fiscal year, we are pleased to be raising our full-year fiscal 2026 non-GAAP EPS and adjusted pre-cash flow guidance.
  • Total company revenue increased 11% to $61 billion. This growth was driven by strong demand in our pharmaceutical and specialty solution segment and in other.

Bear points

  • As a matter of financial transparency, I will note that on a GAAP basis, earnings were impacted by $184 million pre-tax goodwill impairment charge related to our Novista business. The non-cash impairment charge was primarily due to changes in the risk profile of the business plans resulting in an increase in the discount rate.
Read full transcript analysis ›